Publications:

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.

Drug Design, Development And Therapy

Poirier, Steve S; Mayer, Gaétan G

Publication Date: 2013

Variant appearance in text: PCSK9: R218A

PubMed Link: 24115837

Variant Present in the following documents:

• Main text

View BVdb publication page

Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.

The Journal Of Biological Chemistry

Lipari, Michael T MT; Li, Wei W; Moran, Paul P; Kong-Beltran, Monica M; Sai, Tao T; Lai, Joyce J; Lin, S Jack SJ; Kolumam, Ganesh G; Zavala-Solorio, Jose J; Izrael-Tomasevic, Anita A; Arnott, David D; Wang, Jianyong J; Peterson, Andrew S AS; Kirchhofer, Daniel D

Publication Date: 2012-12-21

Variant appearance in text: PCSK9: R218A

PubMed Link: 23135270

Variant Present in the following documents:

• Main text
• zbc43482.pdf

View BVdb publication page